IXICO plc Investor presentation
26 Agosto 2020 - 05:55AM
RNS Non-Regulatory
TIDMIXI
IXICO plc
26 August 2020
IXICO plc
("IXICO" or the "Company")
Investor presentation
IXICO plc (AIM: IXI), the data analytics company delivering
insights in neuroscience, announces that a recording of the online
Company presentation, delivered by Giulio Cerroni, Chief Executive
Officer, and Grant Nash, Chief Finance Officer, on Tuesday 25
August, surrounding the Company's recent trading update, is now
available to watch back on the Investor Meet Company platform. The
Q&A has also been published following the meeting.
Investors can sign up to Investor Meet Company for free and add
to meet IXICO plc via the following link, which will take you to
the recording of the presentation and the Q&A:
https://www.investormeetcompany.com/ixico-plc/register-investor
No new price-sensitive information is disclosed as part of the
presentation.
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive
Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd Tel: 020 7933 8780 or IXICO@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303 /
/
Alice Woodings 07407 804 654
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
mission is to transform the progression of our biopharmaceutical
clients' neurological therapeutic pipelines through the application
of novel imaging and digital biomarkers.
IXICO's data analytics services are used by the global
biopharmaceutical industry to interpret data from brain scans and
digital biosensors to enable better trial design, site
qualification, patient selection and clinical outcomes. We provide
technology-enabled services across all phases of clinical
evaluation. Our integrated digital platform provides a scalable and
secure infrastructure for the capture and analysis of regulatory
compliant clinical data to enable clients to make rapid, better
informed decisions. IXICO is also collaborating with partners to
develop new analytical techniques and companion digital health
products targeted at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Private
Policy.
END
NRAPFMMTMTITBLM
(END) Dow Jones Newswires
August 26, 2020 06:55 ET (10:55 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024